Compounds · subcategory

Tirzepatide

Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion.

30 topics1,716 posts12 solved Moderators: s.leclerc, t.vasquez About this category

tirzepatide SURMOUNT programme SURPASS programme randomised trial effect size

30 topics

Topic	Participants	Replies	Views	Activity
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly tirzepatide SURPASS programme randomised trial effect size Solved Closed Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…	+150	163	22k	11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…	+122	136	48k	9mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…	+109	124	31k	10mo
Follow-up: Tirzepatide's shorter half-life and its one practical consequence tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+130	137	11k	19mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…	+119	136	5.6k	2mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…	+109	122	3.6k	2mo
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's tirzepatide SURPASS programme effect size randomised trial Closed Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here…	+89	101	32k	8mo
Reading SURMOUNT-1 without the press release SURMOUNT programme effect size randomised trial SURPASS programme Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. What changes if the standard account of reading SURMOUNT-1 without the press…	+103	121	7k	7mo
SURPASS-2 and the comparator dose question that will not go away SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…	+101	111	1.5k	18mo
[2026 update] Does dual agonism explain the effect size, or is it dose? SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…	+58	63	40k	9mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version SURMOUNT programme randomised trial effect size tirzepatide Closed On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…	+85	90	13k	7mo
Tirzepatide molecular mass and the charge states you would expect on ESI effect size SURPASS programme SURMOUNT programme randomised trial Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…	+36	40	44k	11mo
Does dual agonism explain the effect size, or is it dose? SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…	+62	68	2.6k	29d
Reading SURMOUNT-1 without the press release — one year on effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…	+45	50	7.6k	5mo
Tirzepatide and nausea: is the profile genuinely different or just differently reported? SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Asking about tirzepatide and nausea directly, because I…	+18	22	37k	8mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version SURMOUNT programme randomised trial effect size tirzepatide Solved Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version A narrow question about GIP…	+48	52	609	10mo
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA tirzepatide effect size randomised trial Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about Tirzepatide in…		2	58k	11mo
Tirzepatide's shorter half-life and its one practical consequence SURPASS programme randomised trial effect size tirzepatide Wiki On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…	+18	29	20k	8mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be tirzepatide SURPASS programme SURMOUNT programme effect size Solved What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what…	+16	20	23k	19h
Tirzepatide storage and stability: what is published versus what is assumed SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…	+17	21	17k	12d
SURMOUNT-4 and what withdrawal data does and does not tell an individual SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…		4	42k	11mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset SURMOUNT programme tirzepatide randomised trial Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Posting a small dataset on 2.5…	+12	16	11k	7mo
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest effect size SURMOUNT programme tirzepatide randomised trial Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…		2	23k	21mo
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA SURMOUNT programme tirzepatide randomised trial effect size Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. Reading back through what has been written here about…	+4	8	14k	8mo
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…	+15	19	930	18mo
Why tirzepatide titration schedules have more steps than semaglutide's SURMOUNT programme SURPASS programme randomised trial tirzepatide Solved Wiki Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's I have spent a fortnight trying to pin tirzepatide titration schedules down…		4	8.4k	7mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that…	+7	11	281	6mo
SURPASS-2 and the comparator dose question that will not go away — what changed since SURMOUNT programme tirzepatide effect size Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…	+2	6	5.5k	7h
About the Tirzepatide category tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
Comparing tirzepatide and semaglutide is harder than the tables suggest SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Reading back through what has been written here…		2	3.8k	10mo

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →